Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Cerebral folate deficiency is defined as a neurological syndrome associated with low CSF 5-methyltetrahydrofolate (5MTHF), the active folate metabolite, in the presence of normal folate metabolism outside the nervous system. Cerebral folate deficiency can result from either disturbed folate transport or from increased folate turnover within the central nervous system.
Biomarker and diagnostic research for cerebral folate deficiency has been reported in the published literature.
1 clinical trial registered, 1 recruiting. Interventions under study include other interventions. Research is primarily sponsored by academic and government institutions.
18 publications have been identified in PubMed for cerebral folate deficiency. Research spans Case Report / Case Series (35%), Review / Meta-Analysis (29%), and Basic Science / Preclinical (12%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 6 | 35% |
Data assembled from 3 of 12 sources · Last updated Sep 19, 2026, 7:50 PM UTC
Research summaries |
5 |
29% |
Laboratory research | 2 | 12% |
Disease patterns and progression | 2 | 12% |
Testing and diagnosis research | 1 | 6% |
Clinical study results | 1 | 6% |
Howard C (2026). [PMID: 41670435](https://pubmed.ncbi.nlm.nih.gov/41670435/). *Curr Opin Pediatr*. [Review / Meta-Analysis]
Mandia D (2026). [PMID: 41506652](https://pubmed.ncbi.nlm.nih.gov/41506652/). *J Inherit Metab Dis*. [Case Report / Case Series]
Unknown (2026). [PMID: 42068313](https://pubmed.ncbi.nlm.nih.gov/42068313/). *Med Lett Drugs Ther*. [Clinical Trial Publication]
Goldman ID (2026). [PMID: 41564421](https://pubmed.ncbi.nlm.nih.gov/41564421/). *N Engl J Med*. [Review / Meta-Analysis]
Santoro JD (2026). [PMID: 41606634](https://pubmed.ncbi.nlm.nih.gov/41606634/). *Mol Autism*. [Diagnostic / Biomarker]
Aboulhassane S (2026). [PMID: 41237996](https://pubmed.ncbi.nlm.nih.gov/41237996/). *J Nutr Biochem*. [Review / Meta-Analysis]
Aboulhassane S (2025). [PMID: 40696390](https://pubmed.ncbi.nlm.nih.gov/40696390/). *Fluids Barriers CNS*. [Basic Science / Preclinical]
Gloor P (2025). [PMID: 40379028](https://pubmed.ncbi.nlm.nih.gov/40379028/). *J Nutr*. [Basic Science / Preclinical]
Ayoub G (2025). [PMID: 40650268](https://pubmed.ncbi.nlm.nih.gov/40650268/). *Int J Mol Sci*. [Review / Meta-Analysis]
Frye RE (2025). [PMID: 40943215](https://pubmed.ncbi.nlm.nih.gov/40943215/). *Int J Mol Sci*. [Epidemiology / Natural History]
AI-curated news mentioning cerebral folate deficiency
Updated Apr 10, 2026
GSK has withdrawn its application for Wellcovorin, initially suggested by the FDA as a potential treatment for cerebral folate deficiency with autistic features. The drug was previously discontinued in 1999, and the FDA had encouraged GSK to refile last September.
The FDA has expanded the label for leucovorin to treat cerebral folate deficiency, an ultrarare condition. This decision highlights a contrasting approach to recent rare disease rejections, emphasizing the agency's evolving stance on evidence requirements.
FDA approves Wellcovorin (leucovorin calcium) for treating cerebral folate transport deficiency, marking a significant advancement for patients with a confirmed variant in the folate receptor 1 gene. This approval expands treatment options for both adult and pediatric patients.
FDA grants expanded approval to Wellcovorin for cerebral folate deficiency (CFD), marking it as the first approved treatment for this ultra-rare disease. The drug is indicated for both children and adults and addresses neurological complications such as seizures and developmental delays.